Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATTERHORN trial of perioperative durvalumab plus FLOT in resectable gastric and gastroesophageal junction cancer
jRCT2031210307Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Randomised, double-blind trial of durvalumab, fluorouracil, folinic acid, oxaliplatin and docetaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by AstraZeneca. Primary endpoint: Event-free survival. Started Jan 2021; status: active, not recruiting.
02
Drugs
durvalumabfluorouracilfolinic acidoxaliplatindocetaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031210307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210307.